XML 183 R71.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 29, 2023
Jun. 28, 2023
Feb. 28, 2023
May 17, 2022
May 17, 2021
Dec. 20, 2018
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Oct. 24, 2023
Interest income             $ 91,326 $ 105,765 $ 406,449 $ 662,859    
Principal repayments             $ 5,398 8,787 35,062 27,786    
Outstanding principal balance                 $ 4,108,913 $ 4,606,227 $ 5,017,987  
Common stock share issued             27,284,633   23,689,135 15,982,472    
Accounts receivable balance             $ 14,251,895   $ 13,478,263 $ 19,759,254    
Prepaid expenses and other current assets - related party             1,383,105   1,310,388 1,811,911    
Impairment charge                 291,980 0    
Revenue             13,712,528 14,584,473 54,426,402 53,376,874    
Loans receivable - related party current portion             666,225   614,473 411,858    
George Terzis [Member]                        
Unpaid salaries and bonuses             76,865   851,000 98,000    
Unpaid salaries and bonuses dues             168,000   168,000      
Common stock share issued                       51,485
Grigorios Siokas [Member]                        
Outstanding principal balance             0   6,194 13,257    
Foreign curreny translation             267   853 436    
Borrowing           $ 1,718,400            
Interest rate           4.70%            
Maturity date           Mar. 18, 2019            
Cana Holdings Laboratories Holding Limited [Member]                        
Secured promissory note     $ 4,457,520                  
Description related to interest on principal     Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023)                  
Interest income     $ 148,789                  
DOC Pharma S.A. [Member]                        
Interest income             45,472 53,235 203,822      
Principal repayments                 310,530      
Interest repayments                 $ 125,816      
Interest rate                 5.50%      
Loan term                 10 years      
Prepayment relates to purchases of inventory             2,900,000   $ 2,600,000      
Maturity date                 Dec. 01, 2032      
Accounts payable and accrued expenses - related party             345,702   $ 249,768 34,217    
Prepaid balance             4,279,200     4,279,200    
Accounts receivable - related party             2,469,234   2,295,706 2,386,721    
Other expenses                     7,599,545  
Prepaid expenses and other current assets - related party             3,549,574   3,284,052 4,347,184    
Cumulative allowance for doubtful accounts             $ 1,400,000   $ 1,400,000      
Agreement terminate                 Dec. 31, 2025      
Pieces per product             1,000 pieces   1,000 pieces      
Purchased of additional licenses                 $ 525,461 734,921    
Loan current portion                   442,480    
Loan non-current portion                 2,898,280 3,539,840    
Impairment charge                 160,947      
Revenue             $ 130,362 384,321 781,386 619,637    
Current portion of Royalty Agreement             378,000   362,000      
Non-current portion of Royalty Agreement             1,889,300   1,811,425      
Research and Development costs                 517,550      
Inventroy purchase             300,208 189,048 1,091,540 1,365,324    
Purchase of branded pharmaceuticals $ 3,539,840 $ 1,965,600                    
Description of research and development       The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022 The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022              
Monthly basis instalments                 35,660      
Loans receivable - related party current portion             768,891   517,550      
Loans receivable - related party noncurrent portion             2,875,384   2,898,280      
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                        
Inventroy purchase             219,645 68,621 533,687 1,237,467    
Dimitrios Goulielmos [Member]                        
Outstanding principal balance             11,012   10,558 11,283    
Foreign curreny translation             454   725 371    
Panagiotis Kozaris [Member]                        
Shares owned                   51,159 $ 143,056  
Prepaid expenses             194,215   194,215 194,215    
Maria Kozari [Member]                        
Accounts receivable balance             1,188,908   1,183,429 1,142,402    
Cumulative allowance for doubtful accounts             773,051   735,000      
Net sales             100,870 86,678 414,443 480,029    
Kanarogloy & Sia Epe [Member]                        
Accounts payable and accrued expenses - related party             15,000   15,000      
Basotho Investment Limited [Member]                        
General and administrative expenses             $ 0 $ 30,900 $ 113,300 $ 10,300    
Common stock share issued             120,000     120,000